UPDATE: Jefferies Starts Cincor Pharma Inc (CINC) at Buy

(Updated - February 1, 2022 4:52 AM EST)

Jefferies analyst Dennis Ding initiates coverage on Cincor Pharma Inc (NASDAQ: CINC) with a Buy rating and a price target of $30.00.

The analyst comments "CINC has a differentiated pill, CIN-107, for difficult to treat high blood pressure in Phase II, plus a slew of other indications, also with blockbuster potential, in Phase I/II. We believe there is a rich catalyst path over the next 12-18 months and, with continued derisking, this could drive the stock towards a $1B+ market cap with long-term M&A optionality, too. Initiate at Buy."

For an analyst ratings summary and ratings history on Cincor Pharma Inc click here. For more ratings news on Cincor Pharma Inc click here.

Shares of Cincor Pharma Inc closed at $19.07 yesterday.

You May Also Be Interested In

• Morgan Stanley Starts Rocket Pharmaceuticals (RCKT) at Overweight, Sees Over 100% Upside
• Sun Pharmaceutical Industries Ltd. (SUNP:IN) PT Raised to INR1,223 at Bernstein
• Advanced Micro Devices (AMD) a victim of its own success - Craig-Hallum